Início › Câncer de Pulmão de Não Pequenas Células › Illinois

Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Illinois

94 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Illinois.

Cidades em Illinois

Texto oficial do estudo (Inglês)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Rush-Copley Medical Center, Aurora
Advocate Good Shepherd Hospital, Barrington
Illinois CancerCare-Bloomington, Bloomington
e mais 42

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The University of Chicago Medical Center ( Site 0118), Chicago

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06623422

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

University of Illinois Cancer Center, Chicago

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06472245

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

OSF Saint Joseph Medical Center, Bloomington
Illinois CancerCare-Bloomington, Bloomington
Illinois CancerCare-Canton, Canton
e mais 19

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07293247

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University of Chicago Hospital, Chicago

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06465069

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

OSF Saint Francis Medical Center, Peoria

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07365319

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #26, Chicago

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05176483

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Illinois Cancer Care ( Site 7000), Peoria

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07513376

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

University of Illinois Cancer Center, Chicago

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06172478

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Illinois CancerCare-Bloomington, Bloomington
Illinois CancerCare-Canton, Canton
Illinois CancerCare-Carthage, Carthage
e mais 23

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07388524

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

Duly Healthcare ( Site 0158), Lisle

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07554339

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Northwestern University, Chicago
Northwestern Medicine Cancer Center Kishwaukee, DeKalb
Northwestern Medicine Cancer Center Delnor, Geneva
e mais 7

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

University of Chicago Medical Center, Chicago
Endeavor Health, Evanston
Illinois Cancer Care, Peoria

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07361497

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Local Institution - 0423, Urbana

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07361510

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Hope And Healing Cancer Services /ID# 276223, Hinsdale

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06772623

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

University of Illinois Cancer Center, Chicago
Center for Care and Discovery, Chicago

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06881784

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare- Bloomington, Bloomington
Illinois Cancer Specialists, Chicago
e mais 7

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

North Shore University Health System ( Site 4014), Evanston
Accellacare of Duly ( Site 4005), Lisle

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Illinois CancerCare - Bloomington, Bloomington
University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
University of Illinois Hospital and Health Sciences System, Chicago
e mais 10

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07222566

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

University of Illinois Chicago, Chicago
Illinois Cancer Specialists, Niles

RecrutandoFase 3

Idades de 18 a 100 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05920356

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Chicago

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06218914

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Hope and Healing Clinical Research, Hinsdale
Hope and Healing Clinical Research, New Lenox

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07489066

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Endeavor Health, Elmhurst
Hope and Healing Cancer Services, Hinsdale
Advocate Medical Group - Libertyville Oncology, Libertyville
e mais 4

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Rush University Medical Center Rush University Cancer Center Chicago, Chicago
University of Illinois at Chicago, Chicago
Cancer Care Specialists of Central Illinois, Decatur
e mais 2

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Rush University Medical Center, Chicago
University of Illinois Chicago, Chicago

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07154290

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Chicago
Research Site, Decatur

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

City of Hope, Chicago, Chicago
University of Illinois at Chicago, Chicago
University of Chicago Medical Center, Chicago
e mais 3

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06890598

Pan-tumor MRD Study

Cancer Care Specialists of Illinois (CCSI), O'Fallon
Carle Health, Urbana

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

OSF Saint Anthony's Health Center, Alton
Rush-Copley Medical Center, Aurora
Illinois CancerCare-Bloomington, Bloomington
e mais 33

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT03191149

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Affiliated Oncologists, LLC, Chicago Ridge

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06561386

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Hinsdale

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06357533

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

OSF Health Care, Peoria

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07140016

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Chicago

RecrutandoFase 2

Idades de 18 a 95 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05061550

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Northwest Oncology & Hematology, Elk Grove Village

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07028489

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

University of Illinois Hospital and Health Sciences System /ID# 275345, Chicago
Illinois Cancer Specialists /ID# 274678, Niles
Springfield Clinic - First /ID# 272576, Springfield

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06568939

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Rush University Medical Center, Chicago

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07100080

An External Control Arm Study in Non-Small Cell Lung Cancer

Northwest Oncology and Hematology, Barrington
Northwest Oncology and Hematology, Elk Grove
Northwest Oncology and Hematology, Hoffman Estates
e mais 1

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07174388

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Illinois Cancer Specialists, Arlington Heights
University of Illinois at Chicago, Chicago
Springfield Clinic Main Campus, Springfield

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06875310

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Northwestern University Feinberg School of Medicine, Chicago

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT05983432

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Chicago
Research Site, Decatur
Research Site, Hinsdale
e mais 1

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06692738

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.